ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 115 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42,615,484 | -25.1% | 1,667,925 | -15.9% | 0.00% | -33.3% |
| Q2 2023 | $56,905,938 | +6.1% | 1,984,168 | -11.3% | 0.00% | 0.0% |
| Q1 2023 | $53,644,836 | -30.0% | 2,237,999 | -50.4% | 0.00% | +50.0% |
| Q4 2022 | $76,586,136 | +89.3% | 4,515,692 | +65.4% | 0.00% | -33.3% |
| Q3 2022 | $40,465,000 | -8.4% | 2,730,462 | -2.7% | 0.00% | 0.0% |
| Q2 2022 | $44,181,000 | -49.1% | 2,806,918 | -12.8% | 0.00% | -25.0% |
| Q1 2022 | $86,756,000 | +14.0% | 3,217,957 | +56.5% | 0.00% | 0.0% |
| Q4 2021 | $76,095,000 | +8.3% | 2,056,074 | +39.8% | 0.00% | 0.0% |
| Q3 2021 | $70,253,000 | +18.2% | 1,470,341 | -16.3% | 0.00% | +33.3% |
| Q2 2021 | $59,411,000 | +2.9% | 1,755,654 | +25.6% | 0.00% | 0.0% |
| Q1 2021 | $57,739,000 | +31.5% | 1,398,035 | +38.2% | 0.00% | 0.0% |
| Q4 2020 | $43,897,000 | -34.4% | 1,011,919 | -35.1% | 0.00% | -40.0% |
| Q3 2020 | $66,935,000 | +455.0% | 1,560,254 | +504.7% | 0.01% | +400.0% |
| Q2 2020 | $12,060,000 | – | 258,022 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |